Physician profile
Michael Pursley
NPI 1467430777
$5,057.93
in general payments reported to CMS, 2019-2025
31 companies · $1,141 in 2025
The $1,141 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.95 · 2020: $248 · 2021: $973 · 2022: $921 · 2023: $930 · 2024: $753 · 2025: $1,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,799 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,798.52 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $625.69 | 2021-2025 | Verquvo, Capvaxive |
| Amgen INC. | $531.67 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $530.97 | 2020-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $489.06 | 2019-2024 | Xarelto |
| Pfizer INC. | $465.31 | 2019-2025 | |
| Welch Allyn | $426.40 | 2021 | |
| Novartis Pharmaceuticals Corporation | $419.80 | 2020-2025 | |
| Boston Scientific Corporation | $329.19 | 2022-2025 | Emblem Mri S-Icd, Accolade Sr, Lux-Dx |
| Sanofi-Aventis U.S. LLC | $221.78 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.32 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $136.89 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Alnylam Pharmaceuticals INC. | $72.22 | 2025 | Amvuttra |
| Abbott Laboratories | $66.99 | 2024 | Jot Dx, Confirm Rx |
| Bayer Healthcare Pharmaceuticals INC. | $66.11 | 2024-2025 | |
| Esperion Therapeutics, INC. | $62.26 | 2021-2025 | Nexletol |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $58.39 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $56.91 | 2020-2023 | Farxiga |
| Baxter Healthcare | $37.11 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Edwards Lifesciences Corporation | $35.93 | 2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $33.90 | 2023 | Arcalyst |
| Atricure, INC. | $28.47 | 2021 | |
| Philips North America LLC | $27.68 | 2024 | (Ck4) Mcot |
| Inspire Medical Systems, INC. | $26.05 | 2025 | Inspire |
| Glaxosmithkline, LLC. | $24.96 | 2025 | Arexvy, Shingrix |
| Kiniksa Pharmaceuticals International, Plc | $20.25 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $18.24 | 2019 | |
| Scpharmaceuticals INC. | $17.12 | 2024 | |
| Cardiovascular Systems INC. | $16.26 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pursley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.